A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial.

Autor:	Hillemanns P; Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany., Denecke A; Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany., Woelber L; Department of Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Böhmer G; IZD Institut für Zytologie und Dysplasie, Hannover, Germany., Jentschke M; Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany., Schjetne KW; Nykode Therapeutics ASA, Oslo, Norway., Bruins Slot KMH; Nykode Therapeutics ASA, Oslo, Norway., Fredriksen AB; Nykode Therapeutics ASA, Oslo, Norway.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Nov 14; Vol. 28 (22), pp. 4885-4892.
DOI:	10.1158/1078-0432.CCR-22-1927
Abstrakt:	Purpose: To evaluate the safety, immunogenicity and efficacy of a therapeutic DNA vaccine VB10.16, using a unique modular vaccine technology that is based on linking antigens to CCL3L1 targeting module, in women with HPV16-positive high-grade cervical intraepithelial neoplasia (CIN). Patients and Methods: We conducted a first-in-human, open-label, phase I/IIa clinical trial of VB10.16 in subjects with confirmed HPV16-positive CIN 2/3. The primary endpoint was the proportion of participants with adverse events, including dose-limiting toxicities. Secondary outcome measures included measuring the E6/E7-specific cellular immune response. In the Expansion cohort HPV16 clearance, regression of CIN lesion size and grading were assessed during a 12-month follow-up period. Results: A total of 34 women were enrolled: 16 in two dose cohorts and 18 in the expansion cohort. No serious adverse events or dose-limiting toxicities were observed, and none of the subjects discontinued treatment with VB10.16 due to an adverse event. Mild to moderate injection site reactions were the most commonly reported adverse event (79%). HPV16-specific T-cell responses were observed after vaccination in the majority of the subjects. In the expansion cohort, HPV16 clearance was seen in 8 of 17 evaluable subjects (47%). Reductions in lesion size were seen in 16 subjects (94%) and 10 subjects (59%) had regression to CIN 0/1. Correlation between strong IFNγ T-cell responses and lesion size reduction was statistically significant (P < 0.001). Conclusions: The novel therapeutic DNA vaccine VB10.16 was well tolerated and showed promising evidence of efficacy and strong HPV16-specific T-cell responses in subjects with high-grade CIN. (©2022 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu